Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics
PA LeWitt - Movement Disorders, 2015 - Wiley Online Library
For all its imperfections at treating Parkinson's disease (PD), orally‐administered levodopa (l‐
dopa) can be regarded as the “platinum” standard of PD therapeutics for its impact on …
dopa) can be regarded as the “platinum” standard of PD therapeutics for its impact on …
Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments
JR Crittenden, AM Graybiel - Frontiers in neuroanatomy, 2011 - frontiersin.org
The striatum is composed principally of GABAergic, medium spiny striatal projection neurons
(MSNs) that can be categorized based on their gene expression, electrophysiological …
(MSNs) that can be categorized based on their gene expression, electrophysiological …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease
Abstract l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
Levodopa-induced motor complications are a common source of disability for patients with
Parkinson's disease. Evidence suggests that motor complications are associated with non …
Parkinson's disease. Evidence suggests that motor complications are associated with non …
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a …
M Andersson, A Hilbertson, MA Cenci - Neurobiology of disease, 1999 - Elsevier
Rats with unilateral dopamine-denervating lesions sustained a 3-week treatment with a daily
l-DOPA dose that is in the therapeutic range for Parkinson's disease. In most of the treated …
l-DOPA dose that is in the therapeutic range for Parkinson's disease. In most of the treated …
The pathophysiology of restricted repetitive behavior
M Lewis, SJ Kim - Journal of neurodevelopmental disorders, 2009 - Springer
Restricted, repetitive behaviors (RRBs) are heterogeneous ranging from stereotypic body
movements to rituals to restricted interests. RRBs are most strongly associated with autism …
movements to rituals to restricted interests. RRBs are most strongly associated with autism …
Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities
Levodopa‐induced motor complications remain an important source of disability for many
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA–induced dyskinesia and the role of dopamine D1 receptors
BACKGROUND: We examined the activation pattern of extracellular signal-regulated kinase
1 and 2 (ERK1/2) and its dependence on D1 versus D2 dopamine receptors in …
1 and 2 (ERK1/2) and its dependence on D1 versus D2 dopamine receptors in …
The serotonergic system in Parkinson's disease
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …